Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.
Saved in:
| Title: | Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. |
|---|---|
| Authors: | Schwarze JK; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium JuliaKatharina.Schwarze@uzbrussel.be., Tijtgat J; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Awada G; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Cras L; Department of Anatomopathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Vasaturo A; Ultivue, Inc, Cambridge, Massachusetts, USA., Bagnall C; Ultivue, Inc, Cambridge, Massachusetts, USA., Forsyth R; Department of Anatomopathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Dufait I; Department of Radiotherapy, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Tuyaerts S; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Van Riet I; Stem Cell Laboratory, Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Neyns B; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Sep; Vol. 10 (9). |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36113895 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Intratumoral administration of CD1c (BDCA-1)<superscript>+</superscript> and CD141 (BDCA-3)<superscript>+</superscript> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Schwarze+JK%22">Schwarze JK</searchLink>; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium JuliaKatharina.Schwarze@uzbrussel.be.<br /><searchLink fieldCode="AU" term="%22Tijtgat+J%22">Tijtgat J</searchLink>; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Awada+G%22">Awada G</searchLink>; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Cras+L%22">Cras L</searchLink>; Department of Anatomopathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Vasaturo+A%22">Vasaturo A</searchLink>; Ultivue, Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bagnall+C%22">Bagnall C</searchLink>; Ultivue, Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Forsyth+R%22">Forsyth R</searchLink>; Department of Anatomopathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Dufait+I%22">Dufait I</searchLink>; Department of Radiotherapy, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Tuyaerts+S%22">Tuyaerts S</searchLink>; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+Riet+I%22">Van Riet I</searchLink>; Stem Cell Laboratory, Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Neyns+B%22">Neyns B</searchLink>; Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2022 Sep; Vol. 10 (9). – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36113895 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2022-005141 Languages: – Code: eng Text: English Titles: – TitleFull: Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Schwarze JK – PersonEntity: Name: NameFull: Tijtgat J – PersonEntity: Name: NameFull: Awada G – PersonEntity: Name: NameFull: Cras L – PersonEntity: Name: NameFull: Vasaturo A – PersonEntity: Name: NameFull: Bagnall C – PersonEntity: Name: NameFull: Forsyth R – PersonEntity: Name: NameFull: Dufait I – PersonEntity: Name: NameFull: Tuyaerts S – PersonEntity: Name: NameFull: Van Riet I – PersonEntity: Name: NameFull: Neyns B IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2022 Sep Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 10 – Type: issue Value: 9 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
